SVB Leerink Research Analysts Lower Earnings Estimates for Pharvaris (NASDAQ:PHVS)

Pharvaris (NASDAQ:PHVS - Become Rating)
had its target toll lowered by research analysts at SVB Leerink from $25.00 to $20.00 in a research notation issued on Wednesday, Stock Target Counselor reports. The brokerage currently has an "outperform" rating on the stock. SVB Leerink's toll target points to a potential upside of 120.51% from the visitor's current price.

PHVS has been the topic of several other reports. Oppenheimer decreased their target price on shares of Pharvaris from $48.00 to $22.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 23rd. Morgan Stanley lowered shares of Pharvaris from an "overweight" rating to an "equal weight" rating and decreased their target price for the visitor from $40.00 to $10.00 in a research study on Tuesday, August 23rd. Bank of America lowered shares of Pharvaris from a "neutral" rating to an "underperform" rating and decreased their target toll for the visitor from $26.00 to $13.00 in a research report on Monday, August 22nd. Finally, JMP Securities decreased their target cost on shares of Pharvaris from $34.00 to $eighteen.00 and gear up a "mkt outperform" rating on the stock in a research report on Tuesday. One analyst has rated the stock with a sell rating, ane has given a hold rating and two accept issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $16.lx.

Pharvaris Price Operation

NASDAQ PHVS opened at $9.07 on Wed. The house has a market capitalization of $288.79 million, a price-to-earnings ratio of -3.49 and a beta of -0.19. The company'due south 50 24-hour interval moving average is $17.03 and its two-hundred day moving boilerplate is $18.05. Pharvaris has a 52-week low of $8.55 and a 52-week high of $27.fifty.

Pharvaris (NASDAQ:PHVS - Get Rating) last posted its quarterly earnings results on Mon, September 12th. The visitor reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.19. As a group, sell-side analysts expect that Pharvaris will post -ii.18 earnings per share for the electric current fiscal year.

Hedge Funds Weigh In On Pharvaris

Institutional investors accept recently added to or reduced their stakes in the company. Suvretta Uppercase Management LLC bought a new position in shares of Pharvaris in the quaternary quarter worth about $11,908,000. Novo Holdings A South raised its stake in shares of Pharvaris by 23.2% in the fourth quarter. Novo Holdings A Due south now owns 516,321 shares of the company'south stock worth $seven,430,000 after acquiring an boosted 97,378 shares during the last quarter. Eventide Nugget Direction LLC raised its stake in shares of Pharvaris past 23.6% in the first quarter. Eventide Asset Direction LLC now owns 302,619 shares of the visitor'southward stock worth $5,659,000 after acquiring an additional 57,694 shares during the last quarter. Viking Global Investors LP raised its stake in shares of Pharvaris past 1.0% in the get-go quarter. Viking Global Investors LP at present owns two,480,319 shares of the company'southward stock worth $46,382,000 later acquiring an additional 24,783 shares during the last quarter. Finally, Depository financial institution of America Corp DE raised its stake in shares of Pharvaris by ane,054.4% in the offset quarter. Depository financial institution of America Corp DE now owns v,772 shares of the company's stock worth $105,000 subsequently acquiring an additional 5,272 shares during the concluding quarter. 70.21% of the stock is endemic past institutional investors.

Pharvaris Visitor Profile

(Get Rating)

Pharvaris Northward.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Stage Two clinical trial for the treatment of hereditary angioedema (HAE).

Featured Articles

• Become a free copy of the StockNews.com inquiry report on Pharvaris (PHVS)
• Is Five Below Trying to Punch As well High?
• These 3 Reports Will Tell United states of america Much Well-nigh the Current Economy
• This Is What To Expect From The S&P 500 Now
• The Two Things You Need To Know About Oracle’s FQ1 Report
• Three Value Stocks For A Volatile Marketplace

This instant news alert was generated by narrative science technology and financial data from MarketBeat in lodge to provide readers with the fastest and about accurate reporting. This story was reviewed past MarketBeat'due south editorial team prior to publication. Please send whatever questions or comments about this story to contact@marketbeat.com.

Should you invest $ane,000 in Pharvaris correct at present?

Before you lot consider Pharvaris, yous'll desire to hear this.

MarketBeat keeps rails of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that superlative analysts are quietly whispering to their clients to buy now before the broader marketplace catches on... and Pharvaris wasn't on the list.

While Pharvaris currently has a "Hold" rating amidst analysts, top-rated analysts believe these 5 stocks are better buys.

View The Five Stocks Here